1. Scrip
  2. >>Therapy Areas

OncoMed Trying To Regroup After Cancer Stem Cell Pipeline Failures

 
• By Emily Hayes

After the Phase II failure of anti-cancer stem cell antibody tarextumab in small-cell lung cancer, another in a string of failures, execs highlight potential of other pipeline assets, including immuno-oncology targets.

OncoMed Pharmaceuticals Inc. is trying to shift focus to its earlier-stage pipeline assets following another pipeline setback – the failure of its anti-cancer stem cell antibody tarextumab, which is partnered with GlaxoSmithKline PLC, in the PINNACLE study in first-line small-cell lung cancer.

The mid-stage PINNACLE study tested tarextumab, which targets Notch 2/3, with etoposide and cisplatin or carboplatin chemotherapy, followed by maintenance tarextumab, versus the same chemotherapy with placebo in 145 previously treated small-cell lung cancer (SCLC) patients. The test drug arm failed the primary endpoint of median progression-free survival (5.6 months for tarextumab versus 5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.